GGrantIndex
Sort

50,496 grants matching lung cancer

A Registry-Based Study of Patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations

$635,757
Christine Veenstra · University Of Michigan At Ann Arbor · R37 · FY2023 · CA

Multi-Pathway DNA Repair Capacity Measurements in Lung Cancer Patients and Healthy Controls

$635,628
Zachary David Nagel · Harvard School Of Public Health · U01 · FY2019 · ES

Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers

$635,583
Sridhar Nimmagadda · Johns Hopkins University · R01 · FY2024 · CA

Impact of mutation burden on cancer growth and the immune landscape

$635,557
Shridar Ganesan · Rutgers Biomedical And Health Sciences · R01 · FY2023 · CA

Lung Tissue Engineering

$635,429
Laura E Niklason · Yale University · R01 · FY2010 · HL

Anaplerotic reprogramming of endothelial cells in pulmonary hypertension

$635,427
Ruslan Rafikov · University Of Arizona · R01 · FY2023 · HL

A Personalized Digital Outreach Intervention for Lung Cancer Screening

$635,420
David P Miller · Wake Forest University Health Sciences · R01 · FY2020 · CA

ELUCIDATING THE ONCOGENIC ROLE OF EMSY IN NON-SMALL CELL LUNG CANCER.

$635,417
Weill Medical College Of Cornell University · · FY2025 · Defense Health Agency

Clinical Laboratory Core

$635,387
Jennifer W Tidey · Brown University · P20 · FY2022 · GM

Anti-tumor immunity and intestinal microbiota are modulated by mitochondrial DNA

$635,296
Douglas C Wallace · Children'S Hosp Of Philadelphia · R01 · FY2025 · CA

Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung Cancer

$635,290
Paul Michael Cinciripini · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA

A model for predicting response to PD-1 inhibitors in NSCLC

$635,258
Edward B Garon · University Of California Los Angeles · R01 · FY2018 · CA

Modified saRNA Encoded BiTEs for Lung Cancer

$635,248
Mark W Grinstaff · Boston University (Charles River Campus) · R01 · FY2025 · CA

Quit2Heal: Rigorous Randomized Trial of a Smartphone Application to Help Cancer Patients Stop Smoking

$635,217
Jonathan B Bricker · Fred Hutchinson Cancer Center · R01 · FY2023 · CA

A model for predicting response to PD-1 inhibitors in NSCLC

$635,207
Edward B Garon · University Of California Los Angeles · R01 · FY2021 · CA

Evaluating Cigarette Relighting Behavior: Prevalence, Correlates, Toxicant Exposure, and Implications for Cessation

$635,190
Michael B. Steinberg · Rutgers Biomedical And Health Sciences · R01 · FY2023 · CA

A model for predicting response to PD-1 inhibitors in NSCLC

$635,187
Edward B Garon · University Of California Los Angeles · R01 · FY2020 · CA

T-cell subsets as CVD risk factors in CHS and MESA

$635,172
Bruce M Psaty · University Of Washington · R01 · FY2016 · HL

Molecular Diagnostics Core Laboratory

$635,058
Mark Raffeld · Division Of Basic Sciences - Nci · ZIC · FY2015 · CA

PQ1: Identification and characterization of genetic alterations for the progression of pre-neoplastic lung lesions by using novel PDx models and deep sequencing

$634,988
David Sidransky · Johns Hopkins University · R01 · FY2020 · CA

RCT of An Internet Cessation Program Plus Online Social Network for HIV + Smokers

$634,880
Jonathan Shuter · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · CA

Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC.

$634,874
Raghuraman Kannan · University Of Missouri-Columbia · R01 · FY2024 · EB

Validation of Immunometabolic NLRX1 Therapeutics for IBD

$634,825
Andrew Leber · Biotherapeutics, Inc. · R44 · FY2020 · DK

Vanberbilt Biomarker Developmental Laboratory

$634,744
Daniel C Liebler · Vanderbilt University · U01 · FY2012 · CA

A novel molecularly targeted theranostic approach via the alphavbeta6 integrin for the detection and treatment of metastatic cancers

$634,742
Julie L Sutcliffe · University Of California At Davis · R01 · FY2024 · CA